Alligator Bioscience EV/FCF

Mitä Alligator Bioscience tekee? Alligator Bioscience AB develops antibody-based cancer immunotherapies using its ALLIGATOR-GOLD and FIND technology platforms. The company focuses on tumor-directed immunotherapies, particularly agonistic mono- and bispecific antibodies. Its pipeline includes three projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody), and ATOR-1016 (bispecific agonistic antibody), all in research/preclinical stages. The company generates revenue through partnerships and licensing agreements with pharmaceutical companies for its antibody development platforms and pipeline candidates. Alligator Bioscience AB targets pharmaceutical companies seeking innovative immunotherapy solutions. The firm's technology platforms, ALLIGATOR-GOLD and FIND, are sold to partners for antibody discovery and optimization. Its pipeline assets, including ATOR-1015 and ATOR-1016, are licensed to partners for further development and commercialization. The company's revenue model relies on upfront payments, milestone payments, and royalties from these partnerships. The company's business model centers on leveraging its proprietary antibody platforms to create value for partners. By offering its technology for discovery and optimization, Alligator Bioscience AB enables pharmaceutical companies to accelerate their immunotherapy drug development. This approach allows the company to monetize its research without directly commercializing drugs, focusing instead on early-stage development and partnership opportunities. Alligator Bioscience on yksi Eurpooliin suosituimmista yhtiöistä.